ARTICLES

1. Fechtner RD, Khouri AS. Evolving global risk assessment of ocular hypertension to glaucoma. Curr Opin Ophthalmol 2007;18(2):104-9.

2. Khouri A, Szirth B, Bhagat N, Fechtner R. Comment on screening and diabetes mellitus. Ophthalmology 2007;
114(2):398-400.

3. Turbin RE, Ahukanna I, Szirth BC, Grant G, Bennett HL, Fechtner RD. Intra-ocular pressure during lumbar disc surgery. Anaesthesia 2007; 62(1):91; [author reply]: 92.

4. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA for the Ocular Hypertension Treatment Study Group. Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2007;125(4):454-9.

5. Khouri AS, Szirth BC, Realini T, Fechtner RD. Comparison of digital and film stereo photography of the optic nerve in evaluation of patients with glaucoma. Telemed J E Health 2006;12(6):632-8.

6. Fechtner RD, et. al. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol 2006;124(9):1257-62.

7. Fechtner R. Glaucoma following intravitreal steroid therapy for age-related macular degeneration. Ophthalmol Times 2006 Mar;(x Suppl):10-11.

8. Khouri AS, Forofonova TI, Fechtner RD. Laser suture lysis through thick blebs using the Blumenthal lens. Arch Ophthalmol 2006;124(4):544.

9. Kymes SM, Kass MA, Anderson DR , Miller JP, Gordon MO for the Ocular Hypertension Treatment Study Group (OHTS). Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006;141(6):997-1008.

10. Khouri AS, Newman FR, Fechtner RD. Ultrasound biomicroscopy demonstrating etiology of a spontaneous filtering bleb. Eye [Internet]. 2006 [2006 Feb. 24].

11. Fechtner R, McCarroll K, Lines C, Adamsons I. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther 2005;21(2):242-9.

12. Parrish RK, Schiffman JC, Feuer WJ, et al., for The Ocular Hypertension Treatment Study (OHTS) Group. Test-retest reproducibility of optic disk deterioration detected from stereophotographs by masked graders. Am J Ophthalmol 2005; 140(4):762-4.

13. Khouri A, Szirth B, Fechtner RD. Detecting age-related macular degeneration: technologies are best compared when standardized [letter]. Arch Ophthalmol 2005;123(8):1157.

14. Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004;138(3 Suppl):19-31.

16. Weinreb R, Friedman D, Fechtner R, et al. Risk assessment in the management of patients with ocular hypertension.
Am J Ophthalmol 2004;138(3):458-67.

17. Realini T, Fechtner RD, Atreides SP, Gollance S. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology 2004;111:421-6.

18. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA, et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82(2):42-8.

19. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5.

20. Higginbotham E, M Gordon, et al. for The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol 2004;122: 813-20.

21. Brandt J, Beiser J, Gordon M, Kass M for The Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2004;138:717-22.

22 Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004;13:168-73.

23. Alvarez TL, Gollance SA, Thomas GA, et al. The Proview phosphene tonometer fails to measure ocular pressure accurately in clinical practice. Ophthalmology 2004;111:1077-85.

24. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol 2003;48:314-46.

25. Keltner J, Johnson C, et al. Classification of visual field abnormalities in the ocular hypertension treatment study.
Arch Ophthalmol 2003;121: 643-50.

26. Kass MA, Heuer DK, Higginbotham EJ, et al. for The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13.

27. Gordon MO, Beiser JA, Brandt JD, et al. for The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.

28. Realini T, Fechtner RD. 56,000 ways to treat glaucoma. Ophthalmology 2002;109(11):1955-6.

29. Delgado MF, Nguyen NT, Cox TA, Singh K, Lee DA, Dueker DK, Fechtner RD, Juzych MS, Lin SC, Netland PA, Pastor SA, Schuman JS, Samples JR. Automated perimetry: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:2362-74.

30. Fechtner RD, Singh K. Maximal glaucoma therapy (review). J Glaucoma 2001;10:S73-S75.

31. Lama PJ, Pagan-Duran B, Eagle RC, Fechtner RD. Toxicity of subconjunctival injection of mitomycin C. Invest Ophthalmol Vis Sci 2001;42(4 Suppl):S545.

32. Essock EA, Sinai MJ, Bryant RD, Fechtner RD, Chen PP, Mills RP. Detection of glaucoma by Fourier analysis of polarimetry data using discriminant analysis. Invest Ophthalmol Vis Sci 2001;42(4 Suppl):S17.

33. Fechtner RD. Combination drug therapy helps patient compliance. Ophthalmology Times 2001 March;26.

34. Fechtner RD. Better compliance possible with combo glaucoma product. Ophthalmology Times 2001 March;25.

35. Fechtner RD. Timolol hemihydrate effective as maleate. Ophthalmology Times 2001 March;22.

36. Fechtner RD. Image analysis: is it ready for clinical practice? Ocular Surgery News 2001 Feb 15;28-9.

37. Fechtner RD. New class of medications of lowering IOP addressed. Ophthalmology Times 2001 Feb;8 -10.

38. Higginbotham EJ, Ball SF, Berlin MJ, Fechtner RD. Developing therapy decisions for the glaucoma patient. EyeWorld 2001 Jan;32.

39. Piltz J, Gross R, Shin D, et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol 2000;130:441-53.

40. Essock EA, Sinai MJ, Fechtner RD, Srinivasan N, Bryant FD. Fourier analysis of nerve fiber layer measurements from scanning laser polarimetry in glaucoma: emphasizing shape characteristics of the 'double-hump' pattern. J Glaucoma 2000;9:444-52.

41. Realini TA, Fechtner RD. Target intraocular pressure in glaucoma management. Glaucoma diagnosis and management 2000;13(3):1-19.

42. Khouri AS, Deebs LS, Tamburro CH, Fechtner RD, Zimmerman TJ. Isolated cotton-wool spot in a patient with hepatitis C. Ann Ophthalmol 2000;32:183 -5.

43. Budo CJ, Baikoff GD, Fechtner RD, Zaldivar R. Cohesive viscoelastics may be useful for phakic IOLs. Ocular Surgery News 2000;18(17):27.

44. Realini T, Fechtner RD. Target intraocular pressure in glaucoma management. Glaucoma diagnosis and management
2000 Sept;407-15.

45. Fechtner RD. Cohesive viscoelastics may be useful for phakic IOLs. Ocular Surgery News 2000 Sept;27-8.

46. Fechtner RD, Lama PJ. The future of glaucoma diagnosis and therapy. Primary care of the glaucomas 2000;
419-25.

47. Fechtner RD. Initial medical management of open-angle glaucoma. J Glaucoma 2000;9:83-6.

48. Sinai MJ, Essock EA, Fechtner RD, Srinivasan N. Diffuse and localized nerve fiber layer loss measured with a scanning laser polarimeter: sensitivity and specificity of detecting glaucoma. J Glaucoma 2000;9:154-62.

49. Bryant FD, Sinai RD, Fechtner RD, Essock EA. An extension of Fourier analysis techniques of nerve fiber layer measurements from scanning laser polarimetry. Invest Ophthalmol Vis Sci 2000;41(4 Suppl):S92.

50. Fechtner RD, Lama PJ. A community based evaluation of efficacy and tolerability of Brimonidine as mono, replacement or combination therapy in African Americans with open angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000;41 Suppl:281.

51. Fechtner RD, Clineschmidt, et al. A three-month parallel, randomized, observer-masked, multicenter study comparing Cosopt to Xalatan in patients with elevated IOP. J Glaucoma 1999;40:S665.

52. Sinai MJ, Essock EA, Fechtner RD. The relationship between retinal nerve fiber layer thickness and basic visual functions. J Glaucoma 1999;40:S659.

53. Fechtner RD, Lama PJ. Advances in optic nerve head analysis in glaucoma. Semin Ophthalmol 1999;
14:180-8.

54. Lama PJ, Fechtner RD. Tube erosion following insertion of a glaucoma drainage device with a pericardial patch graft. Arch Ophthalmol 1999;117:1243-9.

55. Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: design and baseline description of the participants. Arch Ophthalmol 1999;117:573-83.

56. Fechtner RD, Lama P. How to improve your trabeculectomy technique. Rev Ophthalmol 1999; 6:70-79.

57. Essock EA, Sinai MJ, Fechtner RD. Interocular symmetry in nerve fiber layer thickness of normal eyes as determined by polarimetry. J Glaucoma 1999;8:90-98.

58. Realini TA, Fechtner RD. Glaucoma management - what we know about the new medications. Rev Ophthalmol 1998;
59-67.

59. Fechtner RD. Brinzolamide - a new topical carbonic anhydrase inhibitor for glaucoma. The Medical Letter on Drugs and Therapeutics 1998;40:95-6.

60. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41.

61. Fechtner RD. Management of coexisting pseudophakic bullous keratopathy and open-angle glaucoma.
J Glaucoma 1998;7:58-61.

62. Zimmerman TJ, Fechtner RD. Maximal medical therapy for glaucoma. Arch Ophthalmol 1997;115:1579-80.

63. Fechtner RD, Gamero G, Willman M. Nerve fiber layer examination in glaucoma. Mediguide Ophthalmol 1997;7(2):1-6.

64. Zimmerman TJ, Karunaratne N, Fechtner RD. Glaucoma: outcomeology. J Glaucoma 1996;5:151-5.

65. Robison MY, Zimmerman TJ, Fechtner RD. Glaucoma therapy: how and why to do a therapeutic trial.
Rev Ophthalmol 1996:83-5.

66. Essock EA, Fechtner RD, Zimmerman TJ, Krebs WK, Nussdorf JD. Binocular function in early glaucoma.
J Glaucoma 1996;5:395-405.

67. Camras CB, Fechtner RD, Group USLS. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 1996;103:138-47.

68. Camras CB, Alm A, Watson P, Stjernschantz J, Group USLS, Fechtner RD. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after one year of treatment in 198 patients. Ophthalmology 1996;103:1916-23.

69. Sponsel WE, Ritch R, Stamper R, et al. Prevent Blindness America visual field screening study. Am J Ophthalmol 1995;120:699-708.

70. Fechtner RD, Henry JC. VJO case challenge. Video J Ophthalmol 1995;11(3).

71. Fechtner RD. Murray's rule questioned [letter]. EyeCare Technology 1995;5(4):13.

72. Goldbaum MH, Sample PA, White H, et al. Interpretation of automated perimetry for glaucoma by neural network. Invest Ophthalmol Vis Sci 1994;35:3362-73.

73. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma.
Surv Ophthalmol 1994;39:23-42.

74. Fechtner RD, Acland RA. Tubing introducer forceps for glaucoma drainage-tube implants. J Glaucoma 1994;3:79-80.

75. Fechtner RD. Diagnosis with laser scanning ophthalmoscopy. EyeCare Technology 1994(4):19-20.

76. Fechtner RD. Step-by-step trabeculectomy. Video J Ophthalmol 1994;10(6).

77. Weinreb RN, Fechtner RD. Combined cataract and glaucoma surgery. Trans New Orleans Acad Ophthalmol 1993:
151-7.

78. Fechtner RD, Zimmerman TJ. Response to: What do you suggest as the mechanism in a case of intermittent hypotony and how can it be treated? J Cataract Refract Surg 1993;19:807-8.

79. Fechtner RD, Minckler D, Weinreb RN, Frangei G, Jampol LM. Complications of glaucoma surgery: ocular decompression retinopathy. Arch Ophthalmol 1992;110:965-8.

80. Weinreb RN, Fechtner RD. Mechanisms of development of optic nerve damage in primary open angle glaucoma. Jpn J Eye 1990;7:29-35.

BOOKS, MONOGRAPHS AND CHAPTERS

1. Weinreb RN, Fechtner RD, Coleman AL, et al. Treatment of risk in the glaucoma continuum: CME-certified monograph. 2006.

2. Weinreb RN, Fechtner RD , Friedman DS, Liebmann JM, Singh K. Treatment of risk in the glaucoma continuum: CME certified CD-Rom [CD ROM]. 2006.

3. Fechtner RD, Hitchings R. Indications for glaucoma surgery. In: Weinreb RN, Crowston JC, editors. Glaucoma surgery: open angle glaucoma. The Hague, The Netherlands: Kugler; 2005. p 9-20.

4. Fechtner RD, Realini T. What is maximal tolerated medical thearpy? In: Susanna Jr R, Weinreb RN, editors. Glaucoma: answers in glaucoma. Rio de Janeiro, Brazil: Cultura Medica; 2005. p. 95-98.

5. Fechtner RD, Liebmann JM, Singh K. Glaucoma 2005: Mastering tools and techniques for the 21st century. Ophthalmology Times 2005;30(CME supplement 18).

6. Realini T, Fechtner RD. Glaucoma. In: Rakel RE, Bope ET, editors. Conn's current therapy 2003. Philadelphia: WB Saunders; 2003. p 187-190.

7. Fechtner RD, Realini TR. How I treat glaucoma. In: Rakel RE, Bope ET, editors. Conn’s current therapy. Philadelphia: WB Saunders; 2002.

8. Realini T, Fechtner RD. Glaucoma. In: Rakel RD, Bope ET, editors. Conn's current therapy 2002. Philadelphia: WB Saunders; 2002. p 945-948.

9. Fechtner RD, Lama PJ. The future of glaucoma diagnosis and therapy. In: Fingeret M, Lewis TL, editors. Primary care of the glaucomas. 2nd ed. New York: McGraw-Hill; 2001. p 419-26.

10. Fechtner RD. Beta blockers. In: Netland PA, Allen RC, editors. Glaucoma medical therapy: principles and management. San Francisco: American Academy of Ophthalmology. Forthcoming.

11. Realini AR, Khouri AS, Fechtner RD. Key therapeutic signs: retina and vitreous. In: Gross RL, editor. Clinical glaucoma management: critical signs in diagnosis and management. Philadelphia: W B Saunders; 2000. p :383-400.

12. Fechtner RD,editor. New surgical procedures for glaucoma II. Mediguide to Ophthalmology. 1999;9(1):1-8.

13. Fechtner RD,editor. Giant cell (temporal) arteritis. Mediguide to Ophthalmology. 1999;9(4):1-6.

14. Fechtner RD. Beta blockers. In: Allen RC, Netland PA, editors. Glaucoma medical therapy: principles and management. San Francisc : The Foundation of the American Academy of Ophthalmology; 1999. p 25-46.

15. Zimmerman TJ, Kooner K, Sharir M, Fechtner RD. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1997.

16. Fechtner RD, Kooner KS. Definitions and classification of glaucoma. In: Zimmerman TJ, Kooner K, Sharir M, Fechtner RD, editors. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven; 1997.

17. Fechtner RD, Karunaratne N, Nardin G, Zimmerman TJ. Surgery for glaucoma and related conditions. In: Jaffe N, editor. Atlas of ophthalmic surgery. 2nd ed. Philadelphia: J B Lippincott; 1996. p 159-82.

18. Fechtner RD, Ikram F, Essock EA. Advances in quantitative optic nerve analysis. In: Burde RM, Slamovits TL, editors. Volume 3, Advances in clinical ophthalmology. St. Louis: Mosby Year Book; 1996. p 203-24.

19. Fechtner RD, Dreher AW, Weinreb RN. The laser scanning ophthalmoscope. In: Varma R, Spaeth G, Parker K, editors. The Optic disc in glaucoma. Philadelphia: J B Lippincott; 1993. p 269-76.

20. Fechtner RD, Weinreb RN. Examining and recording the appearance of the optic nerve head. In: Starita RJ, editor. Volume 12, Clinical signs in ophthalmology. St. Louis: Mosby Year Book; 1991. p 2-15.

21. Starita RJ, Fechtner RD, Fellman RN. Ocular and systemic side effects of topical epinephrine and dipivefrin. In: Spaeth GL, Sherwood MB, editors. Complications of glaucoma therapy. Thorofare, NJ: SLACK; 1990:19-32.

REVIEWS

1. Khouri A, Fechtner RD. Glaucoma Surgery [review]. J Glaucoma 2005;14(4):328.

2. Fechtner RD. Target IOP for advanced glaucoma. Glaucoma Today 2004 Jan;1-3.

3. Fechtner RD, Lama PJ. Clinical pathways in glaucoma [review]. J Glaucoma 2002; 11:75.

4. Fechtner RD, Lama PJ, Walton W. Atlas of cataract surgery [review]. J Glaucoma 2001;10:501-3.

5. Realini T, Fechtner RD. Target intraocular pressure in glaucoma management. Ophthalmol Clin North Am 2000;13:1-9.

6. Fechtner RD, Lama P. How to improve your trabeculectomy technique [review]. Rev Ophthalmol 1999;VI:70-9

7. Fechtner RD, Lama P. Advances in optic nerve head analysis in glaucoma. Semin Ophthalmol 1999;14:180-188.

8. Realini TA, Fechtner RD. Glaucoma management - what we know about the new medications [review].
Rev Ophthalmol 1998:59-67.

9. Fechtner RD. Source book of ophthalmology [book review]. J Glauocma 1996;5:436.

10. Fechtner RD. Bookends pro [software review]. J Glaucoma 1995;4:300-1.